v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Operating activities    
Net loss $ (35,220) $ (67,961)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities    
Depreciation and amortization 21,704 26,248
Stock-based compensation, net of capitalized cost of $1,318 and $1,292, respectively 25,998 24,638
Change in fair value of warrant liabilities (4,708) (928)
Change in fair value of contingent consideration 676 1,924
Other 1,538 (1,275)
Changes in operating assets and liabilities    
Accounts receivable 2,363 32
Prepaid expenses and other assets 272 1,278
Accounts payable, accrued and other liabilities (4,342) 4,084
Deferred revenue 75,813 (1,149)
Deferred hosting costs 1,026 954
Net cash provided by (used in) operating activities 85,120 (12,155)
Investing activities    
Purchases of property and equipment (28,410) (25,061)
Capitalized internal-use software (2,420) (2,916)
Maturities of available-for-sale securities 27,131 46,808
Sales of available-for-sale securities 9,254 150,211
Purchases of available-for-sale securities (22,361) (81,656)
Business acquisition, net of cash acquired 0 (1,068)
Purchases of licensed imagery intangible assets (892) (4,292)
Other 0 (300)
Net cash provided by (used in) investing activities (17,698) 81,726
Financing activities    
Proceeds from the exercise of common stock options 8,451 300
Payments for withholding taxes related to the net share settlement of equity awards (12,436) (4,485)
Proceeds from employee stock purchase program 1,163 702
Payments of contingent consideration for business acquisitions (4,820) (1,283)
Other (2,521) (340)
Net cash used in financing activities (10,163) (5,106)
Effect of exchange rate changes on cash and cash equivalents, and restricted cash and cash equivalents 5,677 (34)
Net increase in cash and cash equivalents, and restricted cash and cash equivalents 62,936 64,431
Cash and cash equivalents, and restricted cash and cash equivalents at the beginning of the period 129,994 102,198
Cash and cash equivalents, and restricted cash and cash equivalents at the end of the period $ 192,930 $ 166,629